The board of directors, investors, and Michael exchanged an intense debate over the proposed acquisition by Aegis Pharmaceuticals. The conference room was charged with differing opinions, as some board members pointed out the immediate financial gain from the sale, while others raised concerns about the long-term impact on the company's innovations and independence.
"I think we shouldn't sell," one board member, Thomas, said firmly. "The potential for growth in our R&D is too great to give up now. We're on the cusp of breakthroughs that could redefine entire sectors of the medical industry."
On the other side of the argument, another board member, Linda, countered, "But you're not looking at the financial security this deal offers. Two hundred billion is not just a drop in the bucket. It secures our financial future and provides capital for new ventures without the risk."
